Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- MTPC to Merge Its Subsidiary Benesis in October
June 3, 2014
- Astellas Seeks Approval of Cell-Culture Seasonal Flu Vaccine
June 2, 2014
- FDA Approves Eisai’s Aloxi for Pediatric Indication, Grants Additional Six-Month Exclusivity
June 2, 2014
- Announcement: 1st Annual Real World Data Japan 2014 - Tokyo Marriott Hotel, July 15-16
June 2, 2014
- Suglat Secures Top Position in Anterio’s “Mind Share” Ranking in Both GP, HP Markets in April
June 2, 2014
- Astellas, MSD Report 133 ADRs at EPPV for Suglat between January and April
June 2, 2014
- Takeda, US Biotech Venture Agree to Develop, Commercialize Autoimmune Disease Treatment
May 30, 2014
- Europe Approves Takeda’s UC, CD Treatment Entyvio
May 30, 2014
- Daiichi Sankyo to Tout Quick Cardiac Event Reduction for Efient
May 30, 2014
- Bayer Seeks New VTE Indication for Xarelto in Japan
May 30, 2014
- Atypical Antipsychotic Drug Asenapine Significantly Improves Symptoms of Schizophrenia in PIII Trial; Meiji Seika Pharma
May 30, 2014
- Introduction of Joint Bidding System to Result in 100% Price Agreement Rate by September: Mr Takada of Qol
May 30, 2014
- Eisai Receives Positive Opinion from CHMP on Expanded Indication for Halaven for Second-Line Treatment of Advanced Breast Cancer
May 30, 2014
- Shire Japan to Independently Launch Orphan Drug around September
May 29, 2014
- NDA for Once-Yearly Zoledronic Acid Injection Expected in FY2015: Asahi Kasei Pres. Asano
May 29, 2014
- Daiichi Sankyo’s Antiplatelet Agent Efient Now Available in Japan
May 28, 2014
- Novartis to Divest Flu Vaccine Biz within 18 Months
May 28, 2014
- DSP Grants Daiichi Sankyo Commercialization Rights to Lurasidone in South America
May 28, 2014
- GSK Files Long-Acting COPD Drug for Approval in Japan
May 27, 2014
- Taisho Toyama to Center on Safety for Lusefi Promotion: Product Manager
May 27, 2014
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…